Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

85.7%

6 terminated/withdrawn out of 7 trials

Success Rate

14.3%

-72.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

5(71.4%)

N/A

2(28.6%)

7Total

Phase 1(5)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04519684Phase 1Terminated

Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease

Role: lead

NCT05075811Phase 1Terminated

Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease

Role: lead

NCT04519697Phase 1Terminated

Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease

Role: lead

NCT04519671Phase 1Terminated

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

Role: lead

NCT04791878Phase 1Terminated

Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease

Role: lead

NCT06006078Not ApplicableCompleted

Aerosolization During Upper Endoscopy

Role: lead

NCT06257472Not ApplicableWithdrawn

Efficacy of Virtual Reality (VR) for Irritable Bowel Syndrome

Role: lead

All 7 trials loaded